Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma

Yoshihiko Maehara, Yoshihiro Kakeji, Akihiro Watanabe, Hideo Baba, Hiroki Kusumoto, Shunji Kohnoe, Keizo Sugimachi

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND. Mutations of p53 can lead to the production of anti-p53 antibodies in sera of cancer patients. Before this study, the value of preoperative serum anti-p53 antibodies in determining the prognoses of patients with gastric carcinoma had yet to be determined. METHODS. The authors used a highly specific enzyme-linked immunosorbent assay (ELISA) kit (Pharma Cell, France) to determine the preoperative presence of serum anti- p53 antibodies in 120 patients with gastric carcinoma. The relation between the positivity of serum anti-p53 antibodies and p53 abnormal staining of gastric carcinoma tissues was examined. Clinicopathologic characteristics and prognoses of these patients were given attention. RESULTS. Anti-p53 antibodies were detected in 19.2%(23 of 120) of these patients with gastric carcinoma. Among those who were positive for anti-p53 antibodies, female patients were predominant, the depth of invasion was greater, and liver metastasis was present, as compared with those who were negative for anti- p53 antibodies. Regarding other factors, there were no differences between those who were positive or negative for anti-p53 antibodies. Gastric carcinoma tissues had a 60.9%(14 of 23) positivity rate of p53 staining with and-p53 antibodies and a 33.0%(32 of 97) negativity rate, and this difference was statistically significant (P < 0.05). The survival time of patients with anti-p53 antibodies in their sera was shorter than that of subjects with sera negative for anti-p53 antibodies (P < 0.05). The presence of anti-p53 antibodies was not an independent prognostic factor in multivariate analysis. CONCLUSIONS. Serum assay of anti-p53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, depth of invasion, and liver metastasis, and it will show a poorer prognosis for surgically treated patients with gastric carci-noma.

Original languageEnglish
Pages (from-to)302-308
Number of pages7
JournalCancer
Volume85
Issue number2
DOIs
Publication statusPublished - Feb 2 1999

Fingerprint

Anti-Idiotypic Antibodies
Stomach
Carcinoma
Serum
Noma
Staining and Labeling
Neoplasm Metastasis
Liver
France
Neoplasms
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
Mutation
Survival
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Maehara, Y., Kakeji, Y., Watanabe, A., Baba, H., Kusumoto, H., Kohnoe, S., & Sugimachi, K. (1999). Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer, 85(2), 302-308. https://doi.org/10.1002/(SICI)1097-0142(19990115)85:2<302::AID-CNCR6>3.0.CO;2-6

Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. / Maehara, Yoshihiko; Kakeji, Yoshihiro; Watanabe, Akihiro; Baba, Hideo; Kusumoto, Hiroki; Kohnoe, Shunji; Sugimachi, Keizo.

In: Cancer, Vol. 85, No. 2, 02.02.1999, p. 302-308.

Research output: Contribution to journalArticle

Maehara, Y, Kakeji, Y, Watanabe, A, Baba, H, Kusumoto, H, Kohnoe, S & Sugimachi, K 1999, 'Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma', Cancer, vol. 85, no. 2, pp. 302-308. https://doi.org/10.1002/(SICI)1097-0142(19990115)85:2<302::AID-CNCR6>3.0.CO;2-6
Maehara, Yoshihiko ; Kakeji, Yoshihiro ; Watanabe, Akihiro ; Baba, Hideo ; Kusumoto, Hiroki ; Kohnoe, Shunji ; Sugimachi, Keizo. / Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. In: Cancer. 1999 ; Vol. 85, No. 2. pp. 302-308.
@article{158fc44adaae4d92aa03f1f53515b55a,
title = "Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma",
abstract = "BACKGROUND. Mutations of p53 can lead to the production of anti-p53 antibodies in sera of cancer patients. Before this study, the value of preoperative serum anti-p53 antibodies in determining the prognoses of patients with gastric carcinoma had yet to be determined. METHODS. The authors used a highly specific enzyme-linked immunosorbent assay (ELISA) kit (Pharma Cell, France) to determine the preoperative presence of serum anti- p53 antibodies in 120 patients with gastric carcinoma. The relation between the positivity of serum anti-p53 antibodies and p53 abnormal staining of gastric carcinoma tissues was examined. Clinicopathologic characteristics and prognoses of these patients were given attention. RESULTS. Anti-p53 antibodies were detected in 19.2{\%}(23 of 120) of these patients with gastric carcinoma. Among those who were positive for anti-p53 antibodies, female patients were predominant, the depth of invasion was greater, and liver metastasis was present, as compared with those who were negative for anti- p53 antibodies. Regarding other factors, there were no differences between those who were positive or negative for anti-p53 antibodies. Gastric carcinoma tissues had a 60.9{\%}(14 of 23) positivity rate of p53 staining with and-p53 antibodies and a 33.0{\%}(32 of 97) negativity rate, and this difference was statistically significant (P < 0.05). The survival time of patients with anti-p53 antibodies in their sera was shorter than that of subjects with sera negative for anti-p53 antibodies (P < 0.05). The presence of anti-p53 antibodies was not an independent prognostic factor in multivariate analysis. CONCLUSIONS. Serum assay of anti-p53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, depth of invasion, and liver metastasis, and it will show a poorer prognosis for surgically treated patients with gastric carci-noma.",
author = "Yoshihiko Maehara and Yoshihiro Kakeji and Akihiro Watanabe and Hideo Baba and Hiroki Kusumoto and Shunji Kohnoe and Keizo Sugimachi",
year = "1999",
month = "2",
day = "2",
doi = "10.1002/(SICI)1097-0142(19990115)85:2<302::AID-CNCR6>3.0.CO;2-6",
language = "English",
volume = "85",
pages = "302--308",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma

AU - Maehara, Yoshihiko

AU - Kakeji, Yoshihiro

AU - Watanabe, Akihiro

AU - Baba, Hideo

AU - Kusumoto, Hiroki

AU - Kohnoe, Shunji

AU - Sugimachi, Keizo

PY - 1999/2/2

Y1 - 1999/2/2

N2 - BACKGROUND. Mutations of p53 can lead to the production of anti-p53 antibodies in sera of cancer patients. Before this study, the value of preoperative serum anti-p53 antibodies in determining the prognoses of patients with gastric carcinoma had yet to be determined. METHODS. The authors used a highly specific enzyme-linked immunosorbent assay (ELISA) kit (Pharma Cell, France) to determine the preoperative presence of serum anti- p53 antibodies in 120 patients with gastric carcinoma. The relation between the positivity of serum anti-p53 antibodies and p53 abnormal staining of gastric carcinoma tissues was examined. Clinicopathologic characteristics and prognoses of these patients were given attention. RESULTS. Anti-p53 antibodies were detected in 19.2%(23 of 120) of these patients with gastric carcinoma. Among those who were positive for anti-p53 antibodies, female patients were predominant, the depth of invasion was greater, and liver metastasis was present, as compared with those who were negative for anti- p53 antibodies. Regarding other factors, there were no differences between those who were positive or negative for anti-p53 antibodies. Gastric carcinoma tissues had a 60.9%(14 of 23) positivity rate of p53 staining with and-p53 antibodies and a 33.0%(32 of 97) negativity rate, and this difference was statistically significant (P < 0.05). The survival time of patients with anti-p53 antibodies in their sera was shorter than that of subjects with sera negative for anti-p53 antibodies (P < 0.05). The presence of anti-p53 antibodies was not an independent prognostic factor in multivariate analysis. CONCLUSIONS. Serum assay of anti-p53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, depth of invasion, and liver metastasis, and it will show a poorer prognosis for surgically treated patients with gastric carci-noma.

AB - BACKGROUND. Mutations of p53 can lead to the production of anti-p53 antibodies in sera of cancer patients. Before this study, the value of preoperative serum anti-p53 antibodies in determining the prognoses of patients with gastric carcinoma had yet to be determined. METHODS. The authors used a highly specific enzyme-linked immunosorbent assay (ELISA) kit (Pharma Cell, France) to determine the preoperative presence of serum anti- p53 antibodies in 120 patients with gastric carcinoma. The relation between the positivity of serum anti-p53 antibodies and p53 abnormal staining of gastric carcinoma tissues was examined. Clinicopathologic characteristics and prognoses of these patients were given attention. RESULTS. Anti-p53 antibodies were detected in 19.2%(23 of 120) of these patients with gastric carcinoma. Among those who were positive for anti-p53 antibodies, female patients were predominant, the depth of invasion was greater, and liver metastasis was present, as compared with those who were negative for anti- p53 antibodies. Regarding other factors, there were no differences between those who were positive or negative for anti-p53 antibodies. Gastric carcinoma tissues had a 60.9%(14 of 23) positivity rate of p53 staining with and-p53 antibodies and a 33.0%(32 of 97) negativity rate, and this difference was statistically significant (P < 0.05). The survival time of patients with anti-p53 antibodies in their sera was shorter than that of subjects with sera negative for anti-p53 antibodies (P < 0.05). The presence of anti-p53 antibodies was not an independent prognostic factor in multivariate analysis. CONCLUSIONS. Serum assay of anti-p53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, depth of invasion, and liver metastasis, and it will show a poorer prognosis for surgically treated patients with gastric carci-noma.

UR - http://www.scopus.com/inward/record.url?scp=0032890968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032890968&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990115)85:2<302::AID-CNCR6>3.0.CO;2-6

DO - 10.1002/(SICI)1097-0142(19990115)85:2<302::AID-CNCR6>3.0.CO;2-6

M3 - Article

VL - 85

SP - 302

EP - 308

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -